Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHCNASDAQ:CRONTSE:GUDNYSEARCA:THCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Companies$5.42-1.1%$6.23$3.96▼$9.85$1.99B0.432.71 million shs1.35 million shsCRONCronos Group$1.80-2.7%$1.84$1.60▼$3.14$693.73M1.021.42 million shs2.35 million shsGUDKnight TherapeuticsC$5.90+1.2%C$5.80C$5.09▼C$6.45C$596.79M0.570,075 shs25,053 shsTHCXAXS Cannabis ETF$16.60$16.60$14.90▼$25.40$141.07M1.7115,071 shsN/A7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Companies-0.91%+5.76%-20.35%-29.84%-36.72%CRONCronos Group-2.70%+1.69%0.00%-5.26%-27.42%GUDKnight Therapeutics+1.20%+3.69%-2.32%+3.33%+3.15%THCXAXS Cannabis ETF0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHCBausch Health Companies4.0402 of 5 stars2.93.00.04.02.11.71.9CRONCronos Group1.5849 of 5 stars2.05.00.00.02.00.01.3GUDKnight Therapeutics2.1569 of 5 stars3.60.00.00.00.63.30.6THCXAXS Cannabis ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Companies 1.86Reduce$7.1732.23% UpsideCRONCronos Group 0.00N/A$3.5094.44% UpsideGUDKnight Therapeutics 3.25BuyC$7.4826.69% UpsideTHCXAXS Cannabis ETF 2.61Moderate Buy$16.60N/ACurrent Analyst Ratings BreakdownLatest THCX, BHC, CRON, and GUD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/7/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform$9.00 ➝ $8.503/25/2025GUDKnight TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuyC$6.25 ➝ C$7.453/21/2025GUDKnight TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/11/2025GUDKnight TherapeuticsResearch CapitlSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy2/6/2025BHCBausch Health CompaniesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$12.00 ➝ $8.001/30/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$11.00 ➝ $10.00(Data available from 4/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Companies$9.63B0.21$5.77 per share0.94($0.89) per share-6.09CRONCronos Group$117.62M5.90N/AN/A$2.87 per share0.63GUDKnight TherapeuticsC$348.70M1.71C$1.53 per share3.85C$7.65 per share0.77THCXAXS Cannabis ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Companies-$46M-$0.12N/A1.160.37-0.48%-577.82%5.24%4/30/2025 (Estimated)CRONCronos Group-$73.96M$0.10N/A60.001.74-42.65%-2.56%-2.47%5/8/2025 (Estimated)GUDKnight Therapeutics-C$30.73M-C$0.30N/A∞N/A-8.81%-4.04%0.51%N/ATHCXAXS Cannabis ETFN/AN/A0.00∞N/AN/AN/AN/AN/ALatest THCX, BHC, CRON, and GUD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2025Q1 2025BHCBausch Health Companies$1.46N/AN/AN/A$2.29 billionN/A2/19/2025Q4 2024BHCBausch Health Companies$1.65$1.21-$0.44$0.25$2.51 billion$2.56 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CompaniesN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AGUDKnight TherapeuticsN/AN/AN/AN/AN/ATHCXAXS Cannabis ETF$0.724.34%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health CompaniesN/A0.860.62CRONCronos GroupN/A24.2423.05GUDKnight Therapeutics7.523.361.79THCXAXS Cannabis ETFN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Companies78.65%CRONCronos Group8.71%GUDKnight Therapeutics12.58%THCXAXS Cannabis ETFN/AInsider OwnershipCompanyInsider OwnershipBHCBausch Health Companies8.12%CRONCronos Group6.90%GUDKnight Therapeutics45.62%THCXAXS Cannabis ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Companies19,900367.93 million338.06 millionOptionableCRONCronos Group450385.41 million356.14 millionOptionableGUDKnight Therapeutics725101.15 millionN/ANot OptionableTHCXAXS Cannabis ETFN/A8.50 millionN/ANot OptionableTHCX, BHC, CRON, and GUD HeadlinesRecent News About These CompaniesHave Cannabis Investors Been Early Or Wrong Or Both?April 22, 2025 | seekingalpha.comLEEF Brands Begins Planting Salisbury Canyon Ranch, One of the Largest Cannabis Farms in the WorldApril 17, 2025 | globenewswire.comNew Abacus Data Poll Reveals that Most Canadians See Cannabis as a Key Pillar of Canada's Economic FutureApril 16, 2025 | businesswire.comScotts Miracle-Gro Cutting Ties with Cannabis Investments for Now as Federal Legalization StallsApril 10, 2025 | wsj.comScottsMiracle-Gro Continues to Advance Consumer and Cannabis StrategiesApril 10, 2025 | globenewswire.comCannabis Edibles Market Report 2024-2034 Featuring BellRock Brands, Canna River, Wana, Copperstate Farms, Kiva Confections, Wyld, Plant Jam, Dixie Elixirs, Naturecan, Coda Signature, Bhang, UncrateApril 10, 2025 | globenewswire.comHYTN Secures Strategic Supply Agreements and Qualifies 4000kg of Cannabis for German MarketMarch 28, 2025 | globenewswire.comCresco Labs to Operate Kentucky's Largest Medical Cannabis Cultivation LicenseMarch 10, 2025 | businesswire.comOrganigram Reports In-Line Q1 Results As Cannabis Sector TanksFebruary 23, 2025 | seekingalpha.comAurora Cannabis: This Phoenix Has Risen From The Ashes (Strong Buy Initiation)February 22, 2025 | seekingalpha.comHYTN and A1 Cannabis Announce Collaboration Agreements to Scale Production of Cannabis ProductsFebruary 17, 2025 | globenewswire.comCanopy Growth: Q3 Earnings Shows Improvement But Cannabis Sector Remains WeakFebruary 16, 2025 | seekingalpha.comAurora Cannabis Stock Jumps On 'Record-Breaking' Q3 EarningsFebruary 5, 2025 | benzinga.comCannabis Cultivation Market Report 2025, with Profiles of Key Players Pacific Cannabis Growers, Atlas Growers, Canntrust, The Hydropothecary Corporation and Better HoldingsFebruary 4, 2025 | globenewswire.comChristina Lake Cannabis Provides Business UpdateJanuary 31, 2025 | globenewswire.comProfitable New Cannabis Accelerator Combines Social Equity With Merit at Health Advance Inc and SoEquityJanuary 29, 2025 | prnewswire.comNextleaf to Host Live Webinar, Featuring Canadian Cannabis Industry Trends and InsightsJanuary 20, 2025 | newsfilecorp.comHYTN Secures Additional Permits to Expand International GMP Cannabis ExportsJanuary 14, 2025 | globenewswire.comFailed Recreational Vote In Florida Will Not Deter Trulieve CannabisJanuary 2, 2025 | seekingalpha.comCannabis sector limps into 2025 because ‘the gold rush is over'December 27, 2024 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialMicron Tumbles on Tariff Threat: Risk/Reward Outlook ImprovesBy Thomas Hughes | April 11, 2025View Micron Tumbles on Tariff Threat: Risk/Reward Outlook ImprovesTHCX, BHC, CRON, and GUD Company DescriptionsBausch Health Companies NYSE:BHC$5.42 -0.06 (-1.09%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$5.42 +0.00 (+0.09%) As of 04/25/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Cronos Group NASDAQ:CRON$1.80 -0.05 (-2.70%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.81 +0.01 (+0.56%) As of 04/25/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Knight Therapeutics TSE:GUDC$5.90 +0.07 (+1.20%) As of 04/25/2025 04:00 PM EasternKnight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma. The company provides Ladecvina for multiple myeloma and myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Palbocil for breast cancer; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Dolufevir for HIV infection; Exelon for dementia; and Ibsrela for irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for vasomotor symptoms; Fibridoner for idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, it finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is headquartered in Montreal, Canada.AXS Cannabis ETF NYSEARCA:THCX$16.60 0.00 (0.00%) As of 03/1/2024The Cannabis ETF (THCX) is an exchange-traded fund that is based on the AXS Cannabis index. The fund tracks an index of legal cannabis companies selected and weighted by market capitalization. The fund primarily holds North American companies but may also invest in other countries. THCX was launched on Jul 9, 2019 and is managed by AXS Investments. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
